/**/ RNS Number : 9599M IQ-AI Limited 19 September 2023 19 September 2023 IQ-AI Limited (“IQ-AI” or the “Company”) IQ-AI shares cease trading on the OTCQB Venture Market in the United States Further to the announcement of 1 September 2021, IQ-AI Limited (LSE: IQAI) has decided to cease trading on the OTCQB
/**/ RNS Number : 7871L IQ-AI Limited 08 September 2023 8 September 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR Scanners Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the results of a study
/**/ RNS Number : 8096J IQ-AI Limited 18 August 2023 18 August 2023 IQ-AI Ltd (“IQ-AI” or the “Company“) Update on Collaboration Agreement with Mayo Clinic Further to the RNS dated 8 February 2022, IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF) announces that the collaboration agreement signed with the Mayo Clinic for the development
/**/ RNS Number : 8077J IQ-AI Limited 18 August 2023 18 August 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) IB and GE HealthCare Enter into Commercial Agreement IB Neuro and IB Delta T1 to be embedded in GE HealthCare’s (GEHC) MR Smart Subscription Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of
/**/ RNS Number : 5460J IQ-AI Limited 17 August 2023 17 August 2023 IQ-AI Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2023 The Board of IQ-AI Ltd is pleased to announce the Company’s half yearly report for the period ended 30 June 2023. For further information,
/**/ RNS Number : 8411F IQ-AI Limited 13 July 2023 13 July 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) Orphan Drug Designation for GaM in Pediatric GBM Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), today announced the U.S. Food and Drug Administration (US FDA) has
/**/ RNS Number : 3655A IQ-AI Limited 23 May 2023 IQ-AI Limited (“IQ-AI” or the “Company”) Result of AGM IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed. The Directors of the Company accept responsibility for the contents of